Dietrich Wilhelm Schacht

Title: Dietrich Wilhelm Schacht: A Pioneering Inventor in Transdermal Delivery Systems

Introduction:

Dietrich Wilhelm Schacht, a renowned inventor hailing from Köln, Germany, has made significant contributions to the field of transdermal drug delivery systems. With a total of seven patents under his name, Schacht has revolutionized the administration of medications, particularly that of rotigotine. This article delves into his latest patents, career highlights, collaborations, and his impact on the field.

Latest Patents:

Schacht's recent patents have focused on refining the transdermal delivery system for the administration of rotigotine:

1. Transdermal delivery system for the administration of rotigotine:

This patent describes an improved transdermal delivery system (TDS) for the administration of rotigotine. The system consists of a backing layer inert to the matrix components, a self-adhesive matrix containing rotigotine, and a protective foil or sheet to be removed prior to use. Notably, the self-adhesive matrix comprises a solid or semi-solid semi-permeable polymer. This invention offers enhanced drug delivery and improved patient experience.

2. Transdermal delivery system for the administration of rotigotine:

Another innovative patent by Schacht, this delivery system introduces a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer. Within the matrix, rotigotine is contained in the form of microreservoirs. The matrix is highly permeable to the free base of rotigotine but impermeable to the protonated form of the drug. This advancement ensures controlled and efficient drug release.

Career Highlights:

Throughout his career, Dietrich Wilhelm Schacht has contributed extensively to the field of transdermal drug delivery systems. Some notable highlights include his association with the following companies:

1. Schwarz Pharma AG:

Schacht worked with Schwarz Pharma AG, a German pharmaceutical company known for its expertise in innovative drug delivery systems. During his tenure, he played a pivotal role in the development of novel transdermal delivery platforms, driving the company's success in this domain.

2. UCB Pharma GmbH:

Schacht later joined UCB Pharma GmbH, a global biopharmaceutical company committed to creating advanced therapies for severe diseases. Within the company, he continued his groundbreaking work on transdermal delivery systems, solidifying his position as an esteemed inventor in the field.

Collaborations:

Schacht has collaborated with several experts during his career, further elevating his inventiveness and the impact of his work. Notable collaborators include:

1. Hans-Michael Wolff:

Wolff, an esteemed pharmaceutical researcher, has collaborated closely with Schacht on the development of transdermal drug delivery systems. Their collective expertise and shared passion have led to significant advancements in this field.

2. Mike Hannay:

Another valued collaborator, Hannay has contributed to Schacht's research, specifically in the area of transdermal drug delivery systems. Together, they have contributed to the innovation and optimization of drug administration methods.

Conclusion:

Dietrich Wilhelm Schacht's pioneering work in the field of transdermal drug delivery systems, particularly his contributions to the administration of rotigotine, has left an indelible mark. With a remarkable track record of seven patents, his inventions have paved the way for enhanced therapeutic approaches. Schacht's collaborations and career highlights further cement his status as an influential inventor in the field of transdermal drug delivery systems.